The KEYS trial (2022) demonstrated an improvement in overall survival in locally advanced cervical cancer when which agent was added to concurrent chemoradiation?
- A Pembrolizumab ✓
- B Bevacizumab
- C Durvalumab
- D Nivolumab
Correct answer: A. Pembrolizumab
Explanation
The KEYNOTE-A18 (KEYS) trial showed that adding pembrolizumab (anti-PD-1 checkpoint inhibitor) to concurrent cisplatin-based chemoradiation followed by pembrolizumab maintenance significantly improved progression-free survival and overall survival in high-risk locally advanced cervical cancer (Stage IB2-IIB with node-positive or Stage III-IVA). This trial led to FDA approval of pembrolizumab in this setting. Bevacizumab is used in recurrent/metastatic cervical cancer per the GOG-240 trial.
Reference: Shaw's Textbook of Gynaecology, 17th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.